THE STATE OF COMORBID PATHOLOGY IN PATIENTS WITH MORBID OBESITY

Authors

  • I. M. Todurov Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • O. V. Perekhrestenko Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • O. O. Kalashnikov Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • S. V. Kosyukhno Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • V. M. Yakimets Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • O. I. Plehutsa Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine
  • O. A. Potapov Center for Innovative Medical Technologies of NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.11603/1681-2786.2018.2.9362

Keywords:

morbid obesity, comorbid pathology.

Abstract

Purpose: to improve the results of treatment of morbidly obese patients by assessing frequency and characteristics of comorbidity.

Materials and Methods. The results of a preoperative clinical, laboratory, instrumental examination of 205 patients with morbid obesity were analyzed.

Results. Concomitant diseases were diagnosed in 203 (99 %) morbidly obese patients included in the study. In the structure of concomitant pathology cardiovascular diseases prevailed – 135 (65.8 %) patients, carbohydrate metabolism disorders – 135 (65.8 %) patients and lipid metabolism disorders – 161 (78.5 %) patients, reflecting the pathogenesis of the metabolic syndrome and significantly increasing the risk of premature death. Diseases of the respiratory system were diagnosed in 63 (30.7%) patients and digestive system – in 130 (63.4 %) patients.

Conclusions. Peculiarities of morbidly obese patients are high frequency, systemic and, in the most cases, multifocality of organ lesions that requires a systemic implementation of a multidisciplinary approach to improve the results of treatment of this category of patients.

References

Ozhyrinnia – neinfektsiina pandemiia v sviti [Obesity – non-infectious pandemia in the world]. [Elektronnyi resurs]. – Retrieved from: http://www.who.int/gho/ncd/risk_factors/overweight/en/ – Nazva z ekranu.

Busetto, L., Dixon, J., & de Luca, M. (2014). Bariatric surgery in class I obesity: A position statementfrom the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Obes. Surg., 24, 487-519.

Lehnert, T., Sonntag, D., & Konnopka, A. (2013). Economic costs of overweight and obesity. Best Pract. Res. Clin. Endocrinol. Metab., 27 (2), 105-115.

Ng, M., Fleming, T., & Robinson, M. (2014). Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 384, 766-781.

Kang, J.H. & Le, Q.A. (2017). Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Medicine, 96 (46), 8632.

Rubio, M.A. (2014). Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Endocrinol. Nutr., 61 (10), 501-514.

Seidell, J.C. & Halberstadt J. (2015). The global burden of obesity and the challenges of prevention. Ann. Nutr. Metab., 66 (2), 7-12.

Cabrerizo-Garcna, L., Ramos-Levn, A., Moreno-Lopera, C., & RubioHerrera, M.A. (2013). Update on pharmacology of obesity: Benefits and risks. Nutr. Hosp., 28 (5), 121-127.

Yanovski, S.Z. & Yanovski, J.A. (2014). Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 311, 74-86.

Published

2018-09-27

How to Cite

Todurov, I. M., Perekhrestenko, O. V., Kalashnikov, O. O., Kosyukhno, S. V., Yakimets, V. M., Plehutsa, O. I., & Potapov, O. A. (2018). THE STATE OF COMORBID PATHOLOGY IN PATIENTS WITH MORBID OBESITY. Bulletin of Social Hygiene and Health Protection Organization of Ukraine, (2). https://doi.org/10.11603/1681-2786.2018.2.9362

Issue

Section

Health of the population:tendencies and forecasts